Bosentan

Type: Product
Name: Bosentan
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

InterMune Wild Ride Set to Pay Off With Drug: Real M

The 14-year roller-coaster ride for InterMune Inc. (ITMN) shareholders may finally be coming to an end.The stock soared above $50 a handful of times since goingpublic in 2000, and fell below $10 just as often as InterMuneworked on developing the first ... [Published Bloomberg - Aug 14 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

InterMune (ITMN) CEO Dan Welch on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing by. Welcome to the Second Quarter Earnings Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. (Operator ... [Published Seeking Alpha - Aug 07 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Actelion Beats on Q2 Earnings and Sales, Revises View

Actelion Ltd. ’s ( ALIOF ) shares gained 2.97% following the company’s second-quarter 2014 earnings results. In the reported quarter, Actelion reported earnings of $2.83 per American Depository Receipt (:ADR), up 203.77% from the prior-year earnings of ... [Published Yahoo! Finance - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

UPDATE 1-Abuse of U.S. generic-drug rules costs billions -report

(Adds reaction from lawmaker, background on FTC actions)WASHINGTON, July 23 (Reuters) - U.S. rules that ensure prescription medicines are not misused have been manipulated by brand-name drug companies to fight off generic competitors, costing consumers ... [Published CNBC - Jul 23 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Specialty Drugs Transform Lives — But At A Cost

body: Every year, Cora Higson fills out a sheaf of forms and waits several long, anxious days to learn whether a charity will pay for the drug she needs to breathe. The medication — Tracleer — is so essential, Higson says, that she is supposed to call ... [Published AAPS Pharmceutica - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 6 reports

Actelion vows to stay independent as profits rise

After posting a healthy set of financials for the first half of the year, and being mentioned by many as a takeover target, Actelion says its portfolio and pipeline mean that independence is the right path.The Swiss drugmaker’s core operating income jumped ... [Published Pharma Times - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 1 reports

Cost Of Sovaldi And Other Specialty Drugs Worries States, Pharmaceutical Executives

News outlets continue to examine how Solvadi - usually an expensive cure for hepatitis-C - might affect budgets.The Wall Street Journal : Lucrative Drug Niche Sparks Legal ScrambleThe pharmaceutical industry's battle for dominance in the fast-growing ... [Published Kaiser Health News - Jul 21 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Strong first-half 2014 sales and earnings growth for Actelion

Switzerland’s Actelion (SIX: ATLN), Europe’s largest biotech company, this morning posted a strong set of financial results for the first half of 2014, with product sales of 993 million Swiss francs ($1.03 billion), up 17% at constant exchange rates (CER), ... [Published Pharma Letter - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

UPDATE 1-Actelion hikes full-year profit forecast on strong Opsumit launch

6:43am BST* Q2 core earnings 233 mln Sfr vs 171 mln forecast in poll* Expects core earnings growth in at least mid-teens percentage range* Opsumit sales 38 million Swiss francs in second quarter (Adds details)ZURICH, July 22 (Reuters) - Actelion hiked ... [Published Reuters UK - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Specialty drugs save, transform lives — but at a cost

Every year, Cora Higson fills out a sheaf of forms and waits several long, anxious days to learn whether a charity will pay for the drug she needs to breathe.The medication — TracleerTracleer is the brand name for bosentan, a drug that lowers blood pressure ... [Published Boston Globe - Jul 21 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Industry up in arms against NPPA for bringing 108 non-scheduled drugs under price control

The pharmaceutical industry in the country is up in arms against the recent notification of the National Pharmaceutical Pricing Authority (NPPA) in which the national drug price regulator has brought prices of 108 non-scheduled formulation packs involving ... [Published PharmaBiz - Jul 15 2014]
First reported May 08 2014 - Updated May 08 2014 - 2 reports

Orphan designation: Bosentan, for the: Treatment of systemic sclerosis (scleroderma)

Entities: Bosentan, scleroderma

Quotes

André C Muller , Chief Financial Officer, commented: "Excellent product sales, US rebate reversals and ongoing cost control have resulted in core earnings growth of 35 percent - 21 percent excluding the impact of reversals for US rebates accrued in prior years. Since the product contribution has exceeded previous forecasts, we are now able to significantly upgrade our guidance for the full year 2014."
...concerns about whether safety protocols are being inappropriately used to inhibit access to cheaper alternatives," he said in an emailed statement. "The potential savings that this study suggests must be considered as we in Congress continue to work to slow health care spending."
...Hobart Capital Markets trader Justin Haque tells Reuters he has a whole list of companies that might benefit from buying the Swiss high-flyer. "Actelion is the answer to AstraZeneca's chronic pipeline shortage, GlaxoSmithKline's need for expansion and would be an easy morsel for Roche or Novartis to digest" he said
"If there's no bid, there will be pressure on the share price" said Zilian, who has a 'hold' rating on the company

More Content

All (22) | News (19) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
InterMune Wild Ride Set to Pay Off With Drug: R... [Published Bloomberg - Aug 14 2014]
InterMune (ITMN) CEO Dan Welch on Q2 2014 Resul... [Published Seeking Alpha - Aug 07 2014]
Actelion Beats on Q2 Earnings and Sales, Revise... [Published Yahoo! Finance - Jul 24 2014]
ACTELION : delivers strong half year operationa... [Published 4 Traders - Jul 24 2014]
Specialty Drugs Transform Lives — But At A Cost [Published AAPS Pharmceutica - Jul 24 2014]
UPDATE 1-Abuse of U.S. generic-drug rules costs... [Published CNBC - Jul 23 2014]
Actelion vows to stay independent as profits rise [Published Pharma Times - Jul 22 2014]
Actelion's (ALIOF) CEO Jean-Paul Clozel Discuss... [Published Seeking Alpha - Jul 22 2014]
Touting a Q2 beat and strong Opsumit launch, Ac... [Published FiercePharma - Jul 22 2014]
Strong first-half 2014 sales and earnings growt... [Published Pharma Letter - Jul 22 2014]
UPDATE 2-Actelion CEO seeks to diffuse takeover... [Published Reuters - Jul 22 2014]
Actelion Raises Full-Year Profit Forecast on Op... [Published Bloomberg - Jul 22 2014]
Actelion boosts earnings guidance following "st... [Published FirstWord Pharma - Jul 22 2014]
UPDATE 1-Actelion hikes full-year profit foreca... [Published Reuters UK - Jul 22 2014]
Cost Of Sovaldi And Other Specialty Drugs Worri... [Published Kaiser Health News - Jul 21 2014]
Specialty drugs save, transform lives — but at ... [Published Boston Globe - Jul 21 2014]
BB BIOTECH AG: Biotech sector recovers from mar... [Published EuroInvestor - Jul 17 2014]
Industry up in arms against NPPA for bringing 1... [Published PharmaBiz - Jul 15 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Another REMS Antitrust Lawsuit: Mylan Sues Celg... [Published FDA Law Blog - Apr 04 2014]
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: As... [Published Proactiveinvestors United Kingdom RSS feed - Mar 17 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Orphan designation: Bosentan, for the: Treatmen... [Published Orphan designations - May 08 2014]
Another REMS Antitrust Lawsuit: Mylan Sues Celg... [Published FDA Law Blog - Apr 04 2014]
By Kurt R. Karst –In a 17-count, 84-page Complaint filed earlier this week in the U.S. District Court for the District of New Jersey, Mylan Pharmaceuticals Inc. (“Mylan”) alleges that Celgene Corporation (“Celgene”) has violated federal and state antitrust ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.